Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The Mycobacterium tuberculosis CRISPR-Associated Cas1 Involves Persistence and Tolerance to Anti-Tubercular Drugs.

Wei J, Lu N, Li Z, Wu X, Jiang T, Xu L, Yang C, Guo S.

Biomed Res Int. 2019 Apr 2;2019:7861695. doi: 10.1155/2019/7861695. eCollection 2019.

2.

Structure and variation of CRISPR and CRISPR-flanking regions in deleted-direct repeat region Mycobacterium tuberculosis complex strains.

Freidlin PJ, Nissan I, Luria A, Goldblatt D, Schaffer L, Kaidar-Shwartz H, Chemtob D, Dveyrin Z, Head SR, Rorman E.

BMC Genomics. 2017 Feb 15;18(1):168. doi: 10.1186/s12864-017-3560-6.

3.

On the Origin of Reverse Transcriptase-Using CRISPR-Cas Systems and Their Hyperdiverse, Enigmatic Spacer Repertoires.

Silas S, Makarova KS, Shmakov S, Páez-Espino D, Mohr G, Liu Y, Davison M, Roux S, Krishnamurthy SR, Fu BXH, Hansen LL, Wang D, Sullivan MB, Millard A, Clokie MR, Bhaya D, Lambowitz AM, Kyrpides NC, Koonin EV, Fire AZ.

MBio. 2017 Jul 11;8(4). pii: e00897-17. doi: 10.1128/mBio.00897-17.

4.

Cas1 and Cas2 From the Type II-C CRISPR-Cas System of Riemerella anatipestifer Are Required for Spacer Acquisition.

He Y, Wang M, Liu M, Huang L, Liu C, Zhang X, Yi H, Cheng A, Zhu D, Yang Q, Wu Y, Zhao X, Chen S, Jia R, Zhang S, Liu Y, Yu Y, Zhang L.

Front Cell Infect Microbiol. 2018 Jun 12;8:195. doi: 10.3389/fcimb.2018.00195. eCollection 2018.

5.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
6.

Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity.

Nuñez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, Doudna JA.

Nat Struct Mol Biol. 2014 Jun;21(6):528-34. doi: 10.1038/nsmb.2820. Epub 2014 May 4.

7.

How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration.

Xiao Y, Ng S, Nam KH, Ke A.

Nature. 2017 Oct 5;550(7674):137-141. doi: 10.1038/nature24020. Epub 2017 Sep 4.

8.

Spacer capture and integration by a type I-F Cas1-Cas2-3 CRISPR adaptation complex.

Fagerlund RD, Wilkinson ME, Klykov O, Barendregt A, Pearce FG, Kieper SN, Maxwell HWR, Capolupo A, Heck AJR, Krause KL, Bostina M, Scheltema RA, Staals RHJ, Fineran PC.

Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5122-E5128. doi: 10.1073/pnas.1618421114. Epub 2017 Jun 13.

9.

Structural plasticity and in vivo activity of Cas1 from the type I-F CRISPR-Cas system.

Wilkinson ME, Nakatani Y, Staals RH, Kieper SN, Opel-Reading HK, McKenzie RE, Fineran PC, Krause KL.

Biochem J. 2016 Apr 15;473(8):1063-72. doi: 10.1042/BCJ20160078. Epub 2016 Feb 29.

PMID:
26929403
10.

Genotypic drug resistance using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates from North-western Tanzania.

Kidenya BR, Mshana SE, Fitzgerald DW, Ocheretina O.

Tuberculosis (Edinb). 2018 Mar;109:97-101. doi: 10.1016/j.tube.2018.02.004. Epub 2018 Feb 21.

11.

Characterization of Mycobacterium tuberculosis Central Asian Strain 1 using mycobacterial interspersed repetitive unit genotyping.

Ali A, Hasan Z, Tanveer M, Siddiqui AR, Ghebremichael S, Kallenius G, Hasan R.

BMC Microbiol. 2007 Aug 9;7:76.

12.

Genetic Diversity of Mycobacterium tuberculosis Isolates from Assam, India: Dominance of Beijing Family and Discovery of Two New Clades Related to CAS1_Delhi and EAI Family Based on Spoligotyping and MIRU-VNTR Typing.

Devi KR, Bhutia R, Bhowmick S, Mukherjee K, Mahanta J, Narain K.

PLoS One. 2015 Dec 23;10(12):e0145860. doi: 10.1371/journal.pone.0145860. eCollection 2015.

13.

Integrase-mediated spacer acquisition during CRISPR-Cas adaptive immunity.

Nuñez JK, Lee AS, Engelman A, Doudna JA.

Nature. 2015 Mar 12;519(7542):193-8. doi: 10.1038/nature14237. Epub 2015 Feb 18.

14.

Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.

Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, Gujja S, Hamilton S, Howarth C, Larimer JD, Maharaj K, Pearson MD, Priest ME, Zeng Q, Padayatchi N, Grosset J, Young SK, Wortman J, Mlisana KP, O'Donnell MR, Birren BW, Bishai WR, Pym AS, Earl AM.

PLoS Med. 2015 Sep 29;12(9):e1001880. doi: 10.1371/journal.pmed.1001880. eCollection 2015 Sep.

15.

[Population structure analysis of Mycobacterium tuberculosis Beijing family in Japan].

Iwamoto T.

Kekkaku. 2009 Dec;84(12):755-9. Japanese.

PMID:
20077859
16.

M. tuberculosis Central Asian Strain 1 MDR isolates have more mutations in rpoB and katG genes compared with other genotypes.

Ali A, Hasan Z, Moatter T, Tanveer M, Hasan R.

Scand J Infect Dis. 2009;41(1):37-44. doi: 10.1080/00365540802570519. Erratum in: Scand J Infect Dis. 2010 Dec;42(11-12):953-4.

PMID:
19012077
17.

M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania.

Kibiki GS, Mulder B, Dolmans WM, de Beer JL, Boeree M, Sam N, van Soolingen D, Sola C, van der Zanden AG.

BMC Microbiol. 2007 May 31;7:51.

18.

Reconstitution of CRISPR adaptation in vitro and its detection by PCR.

Fagerlund RD, Ferguson TJ, Maxwell HWR, Opel-Reading HK, Krause KL, Fineran PC.

Methods Enzymol. 2019;616:411-433. doi: 10.1016/bs.mie.2018.10.024. Epub 2019 Jan 12.

PMID:
30691653
19.

Transcriptional regulator-mediated activation of adaptation genes triggers CRISPR de novo spacer acquisition.

Liu T, Li Y, Wang X, Ye Q, Li H, Liang Y, She Q, Peng N.

Nucleic Acids Res. 2015 Jan;43(2):1044-55. doi: 10.1093/nar/gku1383. Epub 2015 Jan 7.

20.

Deciphering the sequential events during in vivo acquisition of drug resistance in Mycobacterium tuberculosis.

Singh A, Gopinath K, Singh N, Singh S.

Int J Mycobacteriol. 2014 Mar;3(1):36-40. doi: 10.1016/j.ijmyco.2013.10.006. Epub 2013 Nov 15.

Supplemental Content

Support Center